Visioneering Technologies Inc. (VTI), has presented positive data showing that even after five years, NaturalVue (etafilcon A) multifocal 1 day contact lenses continue to blunt the progression of nearsightedness in children who are wearing the lenses, and over three years of study, substantially slowed progression of axial length.
The updated data include 153 children (mean age 12.0 years) being followed for six to 59 months. The data were consistent at each time point, demonstrating approximately 90% decrease (approximately 1.00D) in myopic progression, as compared to the rate of progression prior to wearing NaturalVue multifocal contact lenses. All time points were statistically significantly different from baseline (p < 0.00001).
Within a subset of 36 children, axial length was measured over time. Axial length change from baseline averaged 0.11 + 0.14mm at 12–17 months (88% reduction in axial length change as compared to baseline), 0.20 + 0.20 (66% reduction) at 18–24 months, and 0.17 + 0.21 (55% reduction) at 30–35 months. There were no reported adverse events related to the contact lenses.
To provide data to practitioners and families on the probability of successful treatment with NaturalVue multifocal contact lenses in the most at-risk patients, a subset analysis of eight to 12 year olds was performed for Number Needed to Treat (NNT). NNT is the number of eyes a practitioner would need to treat in order to see an effect deemed clinically significant. This data suggests for every one eye treated, one eye will show the benefit (no meaningful myopic progression over a three-year period), amounting to meaningful probability of clinical effect.
VTI stated that further research is needed to understand the clinical importance of these data and how the observations relate to long-term outcomes.
CEO Stephen Snowdy, PhD., said, “The long-term effectiveness shown by this new data set for NaturalVue Multifocal is very encouraging, especially when combined with the excellent vision experienced by children wearing the lenses. Our goal is to expand the availability of NaturalVue Multifocal globally and to minimise the amount of myopia progression in as many children as possible.”